Retevmo Side Effects
Generic Name: selpercatinib
Medically reviewed by Drugs.com. Last updated on July 27, 2020.
Note: This document contains side effect information about selpercatinib. Some of the dosage forms listed on this page may not apply to the brand name Retevmo.
For the Consumer
Applies to selpercatinib: oral capsule
Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.
Get emergency medical help if you have signs of an allergic reaction: hives, rash; fever, joint or muscle pain; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
easy bruising or bleeding (nosebleeds, bleeding gums);
coughing up blood or vomit that looks like coffee grounds;
any wound that will not heal;
fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out);
fever, chills, cough with mucus, chest pain, feeling short of breath; or
liver problems--loss of appetite, stomach pain (upper right side), dark urine, jaundice (yellowing of the skin or eyes).
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects may include:
abnormal blood tests;
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to selpercatinib: oral capsule
Very common (10% or more): Leukocytes decreased (43%), platelets decreased (33%), hemorrhage (e.g., epistaxis, hematuria, hemoptysis, contusion, rectal hemorrhage, vaginal hemorrhage, ecchymosis, hematochezia, petechiae, traumatic hematoma, anal hemorrhage, blood blister, blood urine present, cerebral hemorrhage, GI hemorrhage, hemorrhage intracranial, spontaneous hematoma, abdominal wall hematoma, angina bullosa hemorrhagica, diverticulum intestinal hemorrhagic, eye hemorrhage, GI hemorrhage, gingival bleeding, hematemesis, hemorrhagic anemia, intraabdominal hemorrhage, lower GI hemorrhage, melena, mouth hemorrhage, occult blood positive, pelvic hematoma, periorbital hematoma, pharyngeal hemorrhage, pulmonary contusion, purpura, retroperitoneal hematoma, subarachnoid hemorrhage, subdural hemorrhage, upper GI hemorrhage, vessel puncture site hematoma) (15%)
Common (1% to 10%): Hemorrhagic events[Ref]
Common (1% to 10%): Hypersensitivity[Ref]
Very common (10% or more): Glucose increased (44%), albumin decreased (42%), calcium decreased (41%), alkaline phosphatase increased (36%), total cholesterol increased (31%), sodium decreased (27%), magnesium decreased (24%), bilirubin increased (23%), glucose decreased (22%)[Ref]
Very common (10% or more): Increased AST (51%), increased ALT (45%)[Ref]
Very common (10% or more): Fatigue (e.g., fatigue, asthenia, malaise) (35%), edema (e.g., edema, edema peripheral, face edema, eye edema, eyelid edema, generalized edema, localized edema, lymph edema, scrotal edema, peripheral swelling, scrotal swelling, swelling, swelling face, eye swelling, peripheral swelling) (33%)
Frequency not reported: Impaired wound healing[Ref]
The most common adverse reactions, including laboratory abnormalities, (25% or greater) were increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), increased glucose, decreased leukocytes, decreased albumin, decreased calcium, dry mouth, diarrhea, increased creatinine, increased alkaline phosphatase, hypertension, fatigue, edema, decreased platelets, increased total cholesterol, rash, decreased sodium, and constipation.[Ref]
Very common (10% or more): Creatinine decreased (37%)[Ref]
Very common (10% or more): Hypertension (35%), QT prolongation (17%)[Ref]
Very common (10% or more): Rash (e.g., rash erythematous, rash macular, rash maculopapular, rash morbilliform, rash pruritic) (27%)[Ref]
Common (1% to 10%): Hypothyroidism[Ref]
Very common (10% or more): Dry mouth (39%), diarrhea (e.g., diarrhea, defecation urgency, frequent bowel movements, anal incontinence) (37%), constipation (25%), nausea (23%), abdominal pain (e.g., abdominal pain, abdominal pain upper, abdominal pain lower, abdominal discomfort, Gi pain) (23%), vomiting (15%)[Ref]
1. "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.
More about Retevmo (selpercatinib)
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 1 Review
- Drug class: multikinase inhibitors
- FDA Approval History
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.